ALTOPREV
LOE ApproachingSMlovastatin
NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
CLINICAL PHARMACOLOGY The involvement of low-density lipoprotein cholesterol (LDL-C) in atherogenesis has been well-documented in clinical and pathological studies, as well as in many animal experiments. Epidemiological and clinical studies have established that high LDL-C and low high-density…
Indications (13)
risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGYClinical Studies)primary hypercholesterolemia (Types IIaIIb )the response to diet restricted in saturated fatcholesterolto other nonpharmacological measures alone has been inadequatecombined hypercholesterolemiahypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia)it has not been studied in conditions where the major abnormality is elevation of chylomicronsVLDLIDL (ielevated LDL-C levels in patients with combined hypercholesterolemia
Clinical Trials (1)
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Started Nov 2007